Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.53
-0.4%
$4.99
$3.42
$7.20
$254.65M1.751.54 million shs495,179 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.18
+2.2%
$10.70
$4.11
$28.68
$67.02M2.97175,242 shs26,851 shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.76
$0.72
$6.24
$258.25M2.27953,803 shsN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$6.26
-1.9%
$7.47
$6.23
$21.79
$237.59M-0.11134,719 shs118,687 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+0.89%-3.21%+2.03%-23.74%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%-3.51%-18.17%+38.69%+43,779.31%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%+0.50%+335.02%-30.31%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
0.00%-4.43%-10.95%-23.00%-63.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4185 of 5 stars
0.01.00.00.02.90.80.6
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.8353 of 5 stars
3.55.00.00.00.61.70.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.8901 of 5 stars
4.24.00.00.00.02.50.0
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.2625 of 5 stars
3.61.00.00.02.62.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00499.21% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67310.01% Upside

Current Analyst Ratings Breakdown

Latest FBRX, INZY, TRDA, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.03$0.61 per share7.41$7.78 per share0.58
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$210.78M1.13$1.59 per share3.94$11.46 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.1810.30N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$65.63M$0.817.73N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)

Latest FBRX, INZY, TRDA, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.86N/AN/AN/A$8.17 millionN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
8/5/2025Q2 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.36N/AN/AN/AN/AN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
21.88
21.88

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.88 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.53 -0.02 (-0.44%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.54 +0.00 (+0.11%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$10.18 +0.22 (+2.21%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.25 +0.07 (+0.70%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$6.26 -0.12 (-1.88%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.27 +0.01 (+0.16%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.